Summary

U.S. Blood Testing Market Summary

The U.S. blood testing market size was valued at USD 35.90 billion in 2024 and is projected to reach USD 71.41 billion by 2033, growing at a CAGR of 8.1% from 2025 to 2033. The market is primarily driven by the rising prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, which necessitate frequent diagnostic testing and monitoring for effective management.


Growing public awareness and a shift toward preventive healthcare, encouraging routine check-ups and early disease detection screening, are the major drivers for this market. In 2024, the Centers for Disease Control and Prevention (CDC) strengthened its core laboratory capabilities to detect and respond to high-priority pathogens. Recent technological innovations are a major catalyst for the market's expansion, improving the accessibility and efficiency of blood testing. For instance, in June 2024, the FDA granted marketing authorization for the first point-of-care Hepatitis C virus (HCV) RNA test, which enables single-visit testing and treatment using a fingertip blood sample.

Other key technological advances that are expected to impact this market are:

Artificial Intelligence Integration: AI and machine learning were pivotal in interpreting complex blood test data, enabling earlier disease detection, automation of smear analysis, improved biomarker identification, and reduced diagnostic errors. These systems accelerated result delivery and matched or exceeded clinical gold standards in sensitivity and specificity.

Lab-on-a-Chip Technology: Miniaturized devices capable of processing multiple blood tests on a single drop dramatically reduce laboratory demands, increasing access in remote and resource-limited regions while supporting rapid point-of-care diagnostics.

Wearable Biosensors: Smart devices (e.g., glucose and hemoglobin trackers) became possible for monitoring real-time, continuous blood composition. These are integrated with telemedicine platforms, improving chronic disease management, patient engagement, and rapid response to changes in health.

U.S. Blood Testing Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. blood testing market report based on test type:

• Test Type Outlook (Revenue, USD Billion, 2021 - 2033)
o Glucose Testing
o A1C Testing
o Direct LDL testing
o Lipid panel testing
o Prostate-specific antigen testing
o COVID-19 testing
o BUN testing
o Vitamin D testing
o Thyroid-stimulating hormone testing
o Serum Nicotine / Cotinine testing
o High sensitivity CRP testing
o Testosterone testing
o ALT testing
o Cortisol testing
o Creatinine testing
o AST testing
o Other blood tests

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test Type outlook
2.3. Competitive Insights
Chapter 3. U.S. Blood Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. U.S. Blood Testing Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. U.S. Blood Testing Market: Test Type Estimates & Trend Analysis
4.1. Test Type Segment Dashboard
4.2. U.S. Blood Testing Market: Test Type Movement Analysis
4.3. U.S. Blood Testing Market Size & Trend Analysis, by Test Type, 2021 to 2033 (USD Billion)
4.4. Glucose Testing
4.4.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.5. A1C Testing
4.5.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.6. Direct LDL testing
4.6.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.7. Lipid Panel Testing
4.7.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.8. Prostate-Specific Antigen Testing
4.8.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.9. Covid-19 Testing
4.9.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.10. BUN Testing
4.10.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.11. Vitamin D Testing
4.11.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.12. Thyroid-Stimulating Hormone Testing
4.12.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.13. Serum Nicotine/Cotinine Testing
4.13.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.14. High Sensitivity CRP Testing
4.14.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.15. Testosterone Testing
4.15.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.16. ALT Testing
4.16.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.17. Cortisol Testing
4.17.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.18. Creatinine Testing
4.18.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.19. AST Testing
4.19.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
4.20. Other Blood Tests
4.20.1. Market estimates and forecasts 2021 to 2033 (USD Billion)
Chapter 5. Competitive Landscape
5.1. Recent Developments & Impact Analysis, By Key Market Participants
5.2. Company/Competition Categorization
5.3. Vendor Landscape
5.3.1. Key company heat map analysis, 2024
5.4. Company Profiles
5.4.1. Abbott
5.4.1.1. Company overview
5.4.1.2. Financial performance
5.4.1.3. Product benchmarking
5.4.1.4. Strategic initiatives
5.4.2. F. Hoffmann-La Roche Ltd
5.4.2.1. Company overview
5.4.2.2. Financial performance
5.4.2.3. Product benchmarking
5.4.2.4. Strategic initiatives
5.4.3. Bio-Rad Laboratories, Inc.
5.4.3.1. Company overview
5.4.3.2. Financial performance
5.4.3.3. Product benchmarking
5.4.3.4. Strategic initiatives
5.4.4. BIOMÉRIEUX
5.4.4.1. Company overview
5.4.4.2. Financial performance
5.4.4.3. Product benchmarking
5.4.4.4. Strategic initiatives
5.4.5. Biomerica
5.4.5.1. Company overview
5.4.5.2. Financial performance
5.4.5.3. Product benchmarking
5.4.5.4. Strategic initiatives
5.4.6. BD
5.4.6.1. Company overview
5.4.6.2. Financial performance
5.4.6.3. Product benchmarking
5.4.6.4. Strategic initiatives
5.4.7. Quest Diagnostics Incorporated
5.4.7.1. Company overview
5.4.7.2. Financial performance
5.4.7.3. Product benchmarking
5.4.7.4. Strategic initiatives
5.4.8. Siemens Healthineers AG
5.4.8.1. Company overview
5.4.8.2. Financial performance
5.4.8.3. Product benchmarking
5.4.8.4. Strategic initiatives
5.4.9. Danaher Corporation
5.4.9.1. Company overview
5.4.9.2. Financial performance
5.4.9.3. Product benchmarking
5.4.9.4. Strategic initiatives
5.4.10. Trinity Biotech Plc
5.4.10.1. Company overview
5.4.10.2. Financial performance
5.4.10.3. Product benchmarking
5.4.10.4. Strategic initiatives